28,750 Shares in Boston Scientific Corporation $BSX Acquired by Conway Capital Management Inc.

Conway Capital Management Inc. bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,750 shares of the medical equipment provider’s stock, valued at approximately $1,227,000. Boston Scientific accounts for approximately 0.5% of Conway Capital Management Inc.’s holdings, making the stock its 25th biggest position.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Main Street Financial Solutions LLC raised its stake in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC lifted its holdings in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its stake in Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Argus restated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Piper Sandler reaffirmed an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, Truist Financial lowered their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Down 0.7%

NYSE BSX opened at $51.46 on Tuesday. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average is $46.12 and its 200 day moving average is $58.81. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The stock has a market cap of $74.58 billion, a PE ratio of 20.83, a P/E/G ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 202,122 shares of company stock worth $9,813,931. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.